相关临床试验
5
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
已完成
4
80.0%
Unknown
1
20.0%
暂无批准数据
• Elucid appoints key executives including Dr. Amir Ahmadi as chief scientific advisor to spearhead the commercial launch of FDA-cleared PlaqueIQ software for atherosclerosis analysis. • PlaqueIQ becomes the first FDA-cleared non-invasive software that quantifies and classifies plaque morphology based on histology, enabling physicians to make patient-specific treatment decisions. • Recent CMS reimbursement changes double CCTA payments and expand AI-enabled plaque analysis coverage to over 70% of eligible Medicare patients, significantly improving healthcare accessibility.
• Elucid's PlaqueIQ, an AI-driven image analysis software, has secured FDA 510(k) clearance for detecting arterial plaque, a key indicator of cardiovascular disease (CVD). • PlaqueIQ utilizes AI algorithms to enhance CCTA images, quantifying and classifying plaque morphology, including non-calcified plaque and lipid-rich necrotic core (LRNC). • The software aims to provide physicians with detailed, histology-based insights into plaque composition, enabling proactive management of high-risk plaques to prevent heart attacks and strokes. • Elucid plans a limited release of PlaqueIQ later this year and is pursuing further indications for fractional flow reserve measurement.
